Introduction This study aims to assess if the COVID-19 pandemic impacted upon oral cancer staging in a single centre in the UK.Materials and methods Data were collected from the head and neck cancer database of a teaching hospital in London. Oral cancer diagnosis and staging in the peak period of the pandemic (March 2020-2021) were assessed against the one-year period (March 2019-2020) before the pandemic.Results In total, 25 cases of oral cancer were diagnosed in the pre-COVID-19 group compared to 26 in the COVID-19 cohort. Referrals from dentists accounted for 30% of cases of confirmed oral cancer in the COVID-19 class in comparison to 48% the year prior. Higher rates of overall TNM (tumour, lymph node, metastasis) staging at level 4a and above were observed in the COVID-19 cohort at 68% in comparison to 48% the year before.Conclusion Marginal non-statistically significant differences were noted of worsening stages of oral cancer presentations in the first year of the COVID-19 pandemic in this unit. Long-term studies on the outcomes of those diagnosed with oral cancer during the pandemic at a regional and national level will facilitate greater analysis on the impact the pandemic had on this cohort.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41415-024-7056-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A bipartite bacterial virulence factor targets the complement system and neutrophil activation.
EMBO J
January 2025
Philips Institute for Oral Health Research, School of Dentistry, Virginia Commonwealth University, Richmond, VA, USA.
The complement system and neutrophils constitute the two main pillars of the host innate immune defense against infection by bacterial pathogens. Here, we identify T-Mac, a novel virulence factor of the periodontal pathogen Treponema denticola that allows bacteria to evade both defense systems. We show that T-Mac is expressed as a pre-protein that is cleaved into two functional units.
View Article and Find Full Text PDFJanus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder.
Biomaterials
December 2024
Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, 23298, USA; Center for Pharmaceutical Engineering, Center for Drug Discovery, Department of Pediatrics, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, 23298, USA. Electronic address:
The opioid crisis has claimed approximately one million lives in the United States since 1999, underscoring a significant public health concern. This surge in opioid use disorder (OUD) fatalities necessitates improved therapeutic options. Current OUD therapies often require daily clinical visits, leading to poor patient compliance and high costs to the health systems.
View Article and Find Full Text PDFCase Report: osteonecrosis of the maxilla and mandible related to trastuzumab, docetaxel and carboplatin.
Oral Surg Oral Med Oral Pathol Oral Radiol
December 2024
Service of Oral Pathology, João de Barros Barreto University Hospital, Federal University of Para, Belem, Para, Brazil.
We present a case of a patient with HER-2 positive breast cancer who developed extensive areas of osteonecrosis in the mandible and maxilla due to the combination of trastuzumab, carboplatin, and docetaxel. The pathogenesis is discussed based on the literature.
View Article and Find Full Text PDFFacial Lymphedema Following Head and Neck Tumor Resection: Preliminary Experience of Supermicrosurgical Treatment With LVA-Report of Three Cases.
Microsurgery
January 2025
Department of Plastic and Reconstructive Surgery, China Medical University Hospital, Taichung, Taiwan.
Facial lymphedema (FL) is a potential complication following head-and-neck tumor (HNT) therapy. Conservative management is often difficult, and there is limited literature on surgical treatments for FL. This report presents three cases of FL treated with lymphaticovenular anastomosis (LVA).
View Article and Find Full Text PDFFirst-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Cancer Immunol Immunother
January 2025
Oncology Unit, Macerata Hospital, Macerata, Italy.
Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase inhibitors (TKIs), has radically changed the treatment landscape for metastatic RCC, showing varying efficacy across different prognostic groups based on the International Metastatic RCC Database Consortium (IMDC) criteria.
Materials And Methods: This retrospective multicenter study, part of the ARON-1 project, aimed to evaluate the outcomes of favorable-risk metastatic RCC patients treated with immune-based combinations or sunitinib.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!